Translational

BridgeBio has collaborated with two new academic institutions, Columbia University and Mount Sinai (Icahn Mount Sinai), to translate research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.  “Columbia University and Mount Sinai are known for bringing together some of the most talented scientists to develop breakthroughs for patients. By partnering with these world-class […]

Prachi Bogetto leads the Translational Research business at Leica Microsystems, and discusses the importance of imaging innovations when it comes to the fight against cancer. Drug discovery is increasingly informed by scientific insight derived using artificial intelligence (AI). In microscopy, in particular, computational solutions powered by AI and machine learning deliver a deeper understanding of […]

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to contain the spread of COVID-19 […]

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Currently, there is a huge […]

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable […]

Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka. Wioletta is an in vivo translational biologist with over 12 years of experience in renal and cardio-vascular biology bringing thorough knowledge in several different scientific areas […]

Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development. The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial introduction of its Novel Coronavirus antigens, derived […]

The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialisation Fund managed […]

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously untreatable breast cancers. Around three quarters of […]

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer, acknowledges the impact of COVID-19 on the sector […]

Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good Manufacturing Practice (cGMP) clinical supplies of two […]

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies […]

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building on a commitment to the Dementia Discovery […]

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of their ongoing commitment to transparency and openness […]

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends to revamp the scope of pharmacologic interventions […]